Results 21 to 30 of about 10,028,727 (294)

1.2 VASCULAR CALCIFICATIONS AFTER CHRONIC USE OF VITAMIN-K ANTAGONISTS

Artery Research, 2009
Background: Arterial calcification is commonly observed in cardiovascular disease and is associated with increased arterial stiffness, systolic hypertension and adverse cardiovascular outcome.
B.J. van Varik, R.J.M.W. Rennenberg, A.A. Kroon, L.J. Schurgers, P.W. de Leeuw   +4 more
doaj   +1 more source

Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background In this prospective cohort study, we aimed to evaluate the efficacy and safety of direct oral anticoagulants (DOACs) versus heparin/vitamin K antagonists for the treatment of venous thromboembolism (VTE) in patients with inherited ...
Elena Campello, Luca Spiezia, Chiara Simion, Daniela Tormene, Giuseppe Camporese, Fabio Dalla Valle, Anna Poretto, Cristiana Bulato, Sabrina Gavasso, Claudia Maria Radu, Paolo Simioni   +10 more
doaj   +1 more source

Optimization of anticoagulant therapy in patients undergoing mechanical heart valve replacement

Фундаментальная и клиническая медицина, 2023
Acquired heart defects have a high prevalence among patients of different age groups and represent a significant social problem. To date, surgery remains the only effective option to treat acquired heart disease, and replacement of the dysfunctional ...
S. A. Tkachenko, D. A. Astapov, A. V. Bogachev-Prokofiev, A. S. Zalesov, A. N. Pivkin, A. G. Makaev, Kh. A. Agaeva, R. M. Sharifulin   +7 more
doaj   +1 more source

Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study

Haematologica, 2011
Background Poor anticoagulant stability in patients using vitamin K antagonists is a risk factor for both bleeding and thrombosis. In previous studies supplementation with low dose vitamin K1 was shown to improve the stability of anticoagulant control ...
Edward P.A. Gebuis, Frits R. Rosendaal, Erik van Meegen, Felix J.M. van der Meer   +3 more
doaj   +1 more source

The Relationships Between Vitamin K and Cognition: A Review of Current Evidence

Frontiers in Neurology, 2019
Vitamin K is a fat-soluble nutrient discovered in 1935 and its role in blood coagulation has been thoroughly explored. In recent years, studies conducted in vitro and on animals highlighted vitamin K involvement in brain cells development and survival ...
Ludovico Alisi, Roberta Cao, Cristina De Angelis, Arturo Cafolla, Francesca Caramia, Gaia Cartocci, Aloisa Librando, Marco Fiorelli   +7 more
doaj   +1 more source

Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K-1) in severe acute liver disease [PDF]

, 2005
Background/Aims: In patients with severe acute liver dysfunction, i.v. phylloquinone (vitamin K-1) may be given to exclude vitamin K deficiency, rather than impaired hepatic synthesis of coagulation factors alone, as the cause of the coagulopathy ...
Pereira, SP, David Rowbotham, Stephen P. Pereira, Sarah Fitt, Fitt, S, Pereira, S P, Wendon, J, Roger Williams, Williams, R, Julia Wendon, Rowbotham, D, Martin J. Shearer, Shearer, MJ, Shearer, M J   +13 more
core   +1 more source

The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data

Stroke Research and Treatment, 2017
Background and Purpose. Anticoagulant therapy is broadly used to prevent thromboembolic events. Intracranial hemorrhages are serious complications of anticoagulation, especially with warfarin.
Kyle M. Ware, Douglas L. Feinstein, Israel Rubinstein, Prudhvi Battula, Jose Otero, Lee Hebert, Tzu-Fei Wang, Alexandra Ivanova, Shweta Chaudhary, Jessica Hemminger, Sergey V. Brodsky   +10 more
doaj   +1 more source

Proportion of time in therapeutic range (%) for patients on different vitamin K antagonists^*.

, 2016
Proportion of time in therapeutic range (%) for patients on different vitamin K antagonists*.
David A. Fitzmaurice (414003), Sebastian M. Schellong (3280809), A. John Camm (480892), Pantep Angchaisuksiri (3280821), Sylvia Haas (414005), Samuel Z. Goldhaber (414004), Shinya Goto (82609), Janina Stepinska (3280812), Alexander G. G. Turpie (414008), Martin van Eickels (414009), Barry Jacobson (3280827), Lorenzo G. Mantovani (414007), Hugo ten Cate (280615), Gloria Kayani (414012), Harald Darius (78727), Frank Misselwitz (414010), Karen Pieper (3280815), Jean-Pierre Bassand (414002), Ramon Corbalan (3280824), Ajay K. Kakkar (414000), Gabriele Accetta (3280818)   +20 more
core   +1 more source

Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis

Antibiotics, 2021
According to current European Society of Cardiology guidelines, for staphylococcal prosthetic valve endocarditis, rifampicin should be one of the drugs used.
Marcin Wełnicki, Małgorzata Buksińska-Lisik, Artur Mamcarz   +2 more
doaj   +1 more source

Clinical management and outcome of major bleeding in patients on treatment with vitamin K antagonists

, 2016
The optimal management of major bleeding associated with vitamin K antagonists remains ...
Cattinelli, S, Pomero, F, Franco, L, Sbrojavacca, R, BECATTINI, Cecilia, Cappelli, R, Masotti, L, Nitti, C, MANINA, GIORGIA, AGNELLI, Giancarlo   +9 more
core   +1 more source